SELLAS Life Sciences Group, Inc. — Director's Dealing 2013

May 3, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXi Pharmaceuticals Corp (RXII)
CIK: 0001533040
Period of Report: 2013-04-30

Reporting Person: Galena Biopharma, Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-04-30	Common Stock, $0.0001 par value	S	171000	$0.2138	Disposed	33305595	Direct
2013-05-01	Common Stock, $0.0001 par value	S	659500	$0.1925	Disposed	32646095	Direct
2013-05-02	Common Stock, $0.0001 par value	S	253000	$0.1905	Disposed	32393095	Direct

Footnotes

F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.21 to $0.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.19 to $0.21, inclusive.

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.19 to $0.1905, inclusive.